An inhibitor of amyloid-β aggregation
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

DWK-1339

Item No. 27642

Technical Information
Formal Name
2-(3,4-dimethoxyphenyl)-5-(3-methoxypropyl)-benzofuran
CAS Number
1018946-38-7
Synonyms
  • MDR-1339
Molecular Formula
C20H22O4
Formula Weight
Purity
≥95%
A crystalline solid
DMF: 30mg/mLDMSO: 30mg/mLEthanol: 2mg/mL
λmax
214, 315, 329 nm
SMILES
COCCCC1=CC=C2C(C=C(C3=CC(OC)=C(OC)C=C3)O2)=C1
InChi Code
InChI=1S/C20H22O4/c1-21-10-4-5-14-6-8-17-16(11-14)13-19(24-17)15-7-9-18(22-2)20(12-15)23-3/h6-9,11-13H,4-5,10H2,1-3H3
InChi Key
CUEPJIGXQLIOIK-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Wet ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Add

    Product Description

    DWK-1339 is an inhibitor of amyloid-β (Aβ) aggregation.1 It inhibits aggregation of monomeric Aβ (1-42) (Aβ42) and induces disaggregation of Aβ42 fibrils in vitro when used at concentrations ranging from 3.1 to 50 µM. DWK-1339 (10 µM) reduces Aβ42-induced toxicity in HT-22 cells. In vivo, DWK-1339 (10 mg/kg) increases step-through latency in a passive avoidance test and increases spontaneous alteration in the Y-maze compared with vehicle control mice in a mouse model of Aβ42-induced acute Alzheimer's disease. It also decreases brain levels of Aβ42 and increases spontaneous alteration in the Y-maze in the APP/PS1 transgenic mouse model of Alzheimer's disease.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Ha, H., Kang, D.W., Kim, H.-M., et alDiscovery of an orally bioavailable benzofuran analogue that serves as a β-amyloid aggregation inhibitor for the potential treatment of Alzheimer’s disease. J. Med. Chem. 61(1), 396-402 (2018).